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Group O D-negative blood cells are universal donors in transfusion medicine and methods
for converting other blood groups into this universal donor group have been researched.
However, conversion of D-positive cells into D-negative is yet to be achieved, although
conversion of group A or B cells into O cells has been reported. The Rh D blood group is
determined by the RHD gene, which encodes a 12-transmembrane domain protein. Here we
convert Rh D-positive erythroid progenitor cells into D-negative cells using RHD-targeting
transcription activator-like effector nucleases (TALENs). After transfection of TALEN-
encoding plasmids, RHD-knockout clones are obtained. Erythroid-lineage cells differentiated
from these knockout erythroid progenitor cells do not agglutinate in the presence of anti-D
reagents and do not express D antigen, as assessed using ﬂow cytometry. Our programmable
nuclease-induced blood group conversion opens new avenues for compatible donor cell
generation in transfusion medicine.
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B
lood group systems are important for blood transfusion. In
clinical transfusion, the ABO and Rh D blood group
systems are the most critical among 33 human blood group
systems that have been identiﬁed (http://www.isbtweb.org/working-
parties/red-cell-immunogenetics-and-blood-group-terminology/
blood-group-terminology). Because type O Rh D-negative blood
cells are universal donors for transfusion, attempts have been made
to convert other blood groups into type O by enzymatically
removing antigenic carbohydrates1–4. The ABO blood group
type is determined by a glycosyltransferase activity that
attaches a-N-acetylgalactosamine (for group A) or a-D-galactose
(for group B) to the H antigen on the surface of red blood cells.
Furthermore, speciﬁc exoglycosidases that cleave these bonds
between carbohydrate moieties are available and can convert type
A or B cells into type O cells1–4. However, because the Rh D group
is determined by the expression of the RHD protein on blood cells
rather than by the activity of certain enzymes, such enzymatic
manipulations are not a desirable approach for the conversion of
Rh D-positive into D-negative cells, which is yet to be achieved.
The Rh D blood system was discovered in 1940 (ref. 5) and,
since then, a number of other Rh antigens have been identiﬁed.
D is the most immunogenic and clinically important among
50 well-deﬁned antigens in the Rh system6. D antigenicity is
determined by the RHD protein, a 12-transmembrane domain
protein encoded by RHD, a gene on chromosome 1 (refs 7,8).
Roughly 85%, 95% and more than 99.5% of Caucasians, black
Africans and east Asians are D-positive, respectively9. The main
cause of the D-negative phenotype in Caucasians is the
homozygous deletion of the whole RHD gene10. In Africans,
RHD deletion is also the most common mechanism of
D-negativity, but B67% of D-negative Africans have at least
one copy of RHD*C, an RHD allele inactivated by a 37-bp
duplication at the intron 3-exon 4 boundary, which may generate
a frameshift and premature termination codon (PTC), and a
nonsense mutation in exon 6 (ref. 11). Most people are D-positive
or -negative, although a minor fraction of the population are
D-variants, with phenotypes that include weak D, partial D and
DEL12.
The D antigen poses a danger for Rh D-negative people.
Because those who are Rh D-negative do not have naturally
occurring antibodies against the D antigen, adverse effects may
not occur when an Rh D-negative person is ﬁrst exposed to Rh
D-positive cells through blood transfusion or by giving birth to an
Rh D-positive baby. After such an initial exposure, however, an
Rh D-negative person can develop anti-Rh D antibodies, which
can induce immune responses against Rh D-positive cells. When
the Rh D-negative person is again exposed to Rh D-positive cells,
these immune responses can cause adverse effects including
haemolysis or abortion of subsequent D-positive babies. The
ability to convert Rh D-positive into Rh D-negative cells could
provide a starting point for the development of a potential
therapeutic modality for these problems.
Programmable nucleases, which include zinc-ﬁnger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs)
and RNA-guided engineered nucleases (RGENs), enable targeted
genetic modiﬁcations in cells and organisms13. The scope of
programmable nuclease-based genome editing covers gene
disruptions, insertions, point mutagenesis (or correction) and
chromosomal rearrangements such as large deletions, inversions,
duplications and translocations. Gene knockout or disruption is
the simplest form of programmable nuclease-based genome
editing and can be achieved by making a double-stranded break
in a speciﬁc locus using only one or one pair of programmable
nucleases in the absence of donor template. Programmable
nuclease-induced double-stranded breaks can be repaired
through error-prone nonhomologous-end joining, which often
leads to the generation of small insertions or deletions, allowing
gene disruption. We have previously used ZFNs, TALENs
and RGENs to disrupt protein-coding genes in various human
cells14–18.
We postulated that programmable nuclease-based editing of
blood group-determining genes could lead to blood-group
conversion. As a proof-of-concept study, here we disrupted
RHD in Rh D-positive human erythroid progenitor cells using
two different pairs of TALENs. RHD-knockout erythroid
progenitor cells were obtained and gave rise to erythroid-lineage
cells that show an Rh D-negative cell phenotype in ﬂow
cytometry and agglutination tests. These data provide evidence
that blood group conversion can be achieved using program-
mable nuclease-based gene editing.
Results
Design and validation of TALENs targeting RHD. To
completely disrupt the RHD gene, we ﬁrst obtained a TALEN pair
that targets upstream of the protein-coding region; a TALEN pair
targeting exon 1 was prepared (RHD_E1_TALENs; Fig. 1a). We
next determined that this exon 1 target sequence is included in all
transcript variants. Transcript information from NCBI and
Ensembl showed that the human RHD gene has collectively 10
transcript variants including two that do not produce proteins
(Supplementary Fig. 1). Exon 4 is included in all eight coding
sequences, whereas exon 1 is included in seven coding sequences.
Furthermore, exon 4 is the mutation locus of RHD in some Rh
D-negative people11. Thus, we also designed TALENs that target
exon 4 (RHD_E4_TALENs; Fig. 1a).
To validate the activity of the designed TALENs, we transfected
plasmids encoding them into HEK293T cells and performed a
T7E1 assay. The mutation frequencies at the target sites in RHD
exons 1 and 4 were 12% and 6%, respectively (Fig. 1b,c),
indicating that both pairs of TALENs have activity at the
target sites.
Generation of clones containing RHD mutations. We next
attempted to use these TALENs to make RHD-knockout cells
from Rh D-positive erythroid progenitor cells. Our source of
erythroid progenitor cells was the HiDEP-1 cell line, which is
derived from induced pluripotent stem cells generated from
ﬁbroblasts from an Rh D-positive (DD) donor19. For efﬁcient
generation of knockout cells, we used a magnetic reporter
plasmid that expresses H-2Kk in the presence of programmable
nuclease activity at the target sequence as previously
reported15,17,20 (Supplementary Fig. 2). Three days after
co-transfection with the reporter plasmid and plasmids encoding
RHD_E1_TALENs or RHD_E4_TALENs, H-2Kkþ HiDEP-1
cells were magnetically separated15,20 and seeded into 96-well
plates for dilution cloning at an average density of 0.25 cells
per well (Fig. 2a). Individual clones were isolated 17 days after
the clonal cell seeding; genomic DNA was isolated from each
clone and analysed. For efﬁcient screening of mutant clones,
genomic DNA from three (RHD_E1_TALENs) or four
(RHD_E4_TALENs) clones was grouped, mixed and subjected
to the T7E1 assay. This group T7E1 assay showed that six out
of seven clone groups from the RHD_E1_TALEN-transfected
cells and nine out of thirty-seven clone groups from the
RHD_E4_TALEN-transfected cells included at least one mutant
clone (Supplementary Fig. 3). Each individual clone in these
positive clone groups was then subjected to the T7E1 assay. In
cells transfected with RHD_E1_TALENs, this screening identiﬁed
9 mutant clones out of 20 total (Supplementary Fig. 3; Fig. 2b).
Subsequent sequencing analysis showed that these nine
clones comprise seven monoallelic out-of-frame mutant clones,
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1 monoallelic in-frame mutant clone (3 nucleotide deletion), and
1 biallelic mutant clone that contains one in-frame mutation
(6 nucleotide deletion) and one out-of-frame mutation
(2 nucleotide deletion)(Supplementary Fig. 4a). Because in-frame
mutations can lead to incomplete gene knockout, we attempted to
obtain biallelic out-of-frame mutant clones. For this purpose, we
again co-transfected the reporter plasmid and the plasmids
encoding RHD_E1_TALENs into one (#17) of the 7 monoallelic
out-of-frame mutant clones and performed clonal culture after
magnetic separation. Sequencing of DNA from 7 subclones
derived from this monoallelic mutant clone showed that all the
subclones contain the 2 nucleotide deletion that was initially
observed in the parent clone. Among the 7 subclones, one
subclone (#17-3), which contained biallelic out-of-frame
mutations, was designated as E1_B (#17-3; Supplementary
Fig. 4b) and expanded for additional study.
Similarly, in cells co-transfected with the reporter plasmid and
the plasmid encoding RHD_E4_TALENs, the two-step T7E1
assay revealed that 7 out of 148 clones contain mutations near the
target sites in exon 4 (Supplementary Fig. 3; Fig. 2b). Sequencing
showed that these seven clones comprise four monoallelic in-
frame mutant clones (#33, #37, #53 and #122), one monoallelic
out-of-frame mutant clone (#8) and two biallelic out-of-frame
mutant clones (#5, #118; Supplementary Fig. 4c). One of the two
biallelic mutant clones and the monoallelic out-of-frame mutant
clone were designated as E4_B (#5) and E4_M (#8), respectively,
and expanded for further experiments.
We next examined the sequencing results to determine
whether the selected mutant clones have PTCs in RHD exons.
Both RHD alleles of clone E1_B had PTCs within exon 1 (Fig. 3a).
In clone E4_B, PTCs were observed in exon 4 of one allele and in
exon 5 of the other (Fig. 3b). In clone E4_M, a PTC was in exon 4
of one mutated allele (Fig. 3c). We have indicated the locations of
the PTCs in a two-dimensional (2D) model of the RHD protein
in Supplementary Fig. 5. Taken together, these results indicate
that the RHD protein will be expressed in clone E4_M but not in
E1_B or E4_B.
Off-target mutations in the mutant clones. We investigated
whether the RHD-mutant clones contain off-target mutations
induced by the TALEN pairs. Potential off-target sites were
predicted using a web-based programme called PROGNOS
(Predicted Report Of Genome-wide Nuclease Off-target Sites)21
(Supplementary Data set 1) and the two top ranking sites for
RHD_E1_TALENs and the three top ranking sites for
RHD_E4_TALENs were chosen for further analysis. For both
TALEN pairs, the highest ranking off-target sites were in the
RHCE gene, which has high homology with the RHD gene22. The
potential off-target site for the RHD_E1_TALENs in RHCE
showed a perfect match with the target sequence; the T7E1 assay
revealed mutations at that off-target site in the E1_B clone
(Supplementary Fig. 6a). Sequencing of that region in the E1_B
clone showed six sequences with a three-nucleotide deletion and
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11
5′
3′
5′
3′ 5′
3′
5′
RHD_E4_TALENsFokl
Fokl
Fokl
Fokl
NI
2.0
M Unt
rans
fect
ed
RH
D_E
1_T
ALE
Ns
M Unt
rans
fect
ed
RH
D_E
1_T
ALE
Ns
1.0
0.5
(kbp)
2.0
1.0
0.5
(kbp)
6 Indels (%)12 Indels (%)
NG HD NN
RHD locus
RHD_E1_TALENs
3′
Figure 1 | TALENs targeting the human RHD gene. (a) Schematic of the TALEN-targeting sites in the RHD gene. Blue boxes indicate exons.
RHD_E1_TALENs and RHD_E4_TALENs represent the TALEN pairs that target sequences (shown in a red colour) in exon 1 and exon 4, respectively.
The red, yellow, green and purple rectangular boxes in the TALENs symbolize the TALE repeat units that recognize guanine, thymine, cytosine and adenine,
respectively. (b,c) T7E1 assay using 293T cells after transfection with plasmids encoding TALENs targeting RHD exon 1 (b, RHD_E1_TALENs) or exon 4
(c, RHD_E4_TALENs), respectively. The sizes of marker (M) bands are shown on the left (kbp, kilobase pairs). Arrows indicate the expected positions of
DNA bands cleaved by T7E1. The numbers at the bottom of the gel indicate mutation percentages measured by band intensities.
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four sequences with another three-nucleotide deletion, suggesting
biallelic heterogeneous in-frame deletions at the RHCE locus
(Supplementary Fig. 6b). The potential off-target site for the
RHD_E4_TALENs in RHCE had a two base pair mismatch as
compared with the target sequence; the T7E1 assay revealed
mutations in E4_B but not E4_M (Supplementary Fig. 6c).
Sequencing of that region in clone E4_B showed ﬁve wild-type
sequences and ﬁve sequences with a 16-nucleotide deletion,
indicating a monoallelic mutation (Supplementary Fig. 6d).
Sequencing in clone E4 revealed 10 wild-type sequences,
corroborating the absence of mutations in that region. In
addition, in all three analysed clones, the T7E1 assay showed
no mutations at the remaining other potential off-target sites
outside of the RHCE gene (Supplementary Fig. 6a,c).
RHD mRNA expression in mutant clones. We next examined
RHD mRNA expression in parental, E1_B, E4_B and E4_M
HiDEP-1 cells using RT–PCR. Electrophoresis of the RT–PCR
products from parental HiDEP-1 cells showed a dense band at
B1.4 kb, a medium-density band atB1.3 kb and a weak band at
B1.1 kb (Fig. 4a). The two higher molecular weight bands were
also clearly observed in E1_B and E4_M samples as well. To
identify these bands, we cloned the RT–PCR products into
T-vectors and performed capillary sequencing. The results
showed that transcript variant 1, which lacks exon 8, and a new
transcript variant 1, which lacks both exons 7 and 8, were
observed at frequencies of 8/19 and 4/19 in parental cells, 6/15
and 4/15 in E1_B and 10/20 and 8/20 in E4_M, respectively,
accounting for the two most frequently observed transcript
variants in parental (8/19þ 4/19¼ 63%), E1_B (6/15þ 4/15
¼ 67%) and E4_B (10/20þ 8/20¼ 90%; Fig. 4b). Furthermore,
the expected sizes of variant 1 and the new variant 1 are 1,422 and
1,288 bp, respectively. Taken together, these results indicate that
the dense band at 1.4 kb and the medium-density band at 1.3 kb
are variant 1 and new variant 1, respectively, and suggest that
these two transcript variants are dominant in HiDEP-1 cells.
To determine whether these RHD mRNA variants are speciﬁc
to HiDEP-1 cells, an erythroid cell line derived from induced
pluripotent stem cells, we performed RT–PCR using RNA from
two other kinds of erythroid cells: erythroid cells differentiated
from primary human cord blood CD34þ cells23 and HUDEP-2
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Figure 2 | Generation of RHD-mutated erythroid progenitor cells. (a) Schematic representation illustrating the process of RHD-mutated clone generation.
Clonal culture of HiDEP-1 erythroid progenitor cells was initiated 3 days after transfection with plasmids encoding TALENs that target RHD. Genomic
DNA from each clone was analysed 17 days after the initiation of clonal culture. (b) T7E1-based clonal analysis. The genomic DNA isolated from each
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Figure 3 | DNA sequences of RHD-mutated clones. The RHD gene DNA sequences from the parental cells, clones with biallelic mutations in exon 1
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cells, an immortalized erythroid progenitor cell line derived from
cord blood CD34þ cells19. Electrophoresis of the products from
the two RT–PCRs showed the three bands, that is, a dense band at
B1.4 kb, a medium-density band atB1.3 kb and a weak band at
B1.1 kb, although the band at B1.1 kb was too faint to be
observed in the HUDEP-2 mRNA (Fig. 4a). The similarity of the
electrophoresis patterns of the RT–PCR products of the HiDEP-1
cells and the two different erythroid-lineage cells derived from
CD34þ cells suggests that the RHD mRNA variants observed in
the parental clone are not speciﬁc to HiDEP-1 cells. Furthermore,
sequencing of these RT–PCR products showed that the RHD
mRNA variants observed in the parental and E1_B and E4_M
clones were also observed in both cell types derived from
CD34þ cells at comparable frequencies (Supplementary Fig. 7),
corroborating that RHD mRNA variants are not speciﬁc to cells
derived from induced pluripotent stem cells.
These two bands, however, were not observed in the
electrophoresis of E4_B RT–PCR products, which instead showed
three weak, wide bands with a size range of B0.7B1.1 kb.
Sequencing of E4_B RHD transcripts revealed 11 transcript
variants that were not observed in the other cells and have not
been previously reported. Interestingly, all 11 observed transcript
variants lack exon 4, the site where TALEN-induced mutations
were induced. Taken together, the results indicate that the two
mutations in exon 4 in clone E4_B lead to an alteration in RHD
RNA splicing coupled with a reduced mRNA level.
In parental, E1_B, and E4_M HiDEP-1 cells, sequencing
disclosed new transcript variants that have not been previously
reported; these new variants are referred to as new transcript
variants 1, 2 and 3, respectively, in this manuscript. In addition,
sequencing also revealed that the TALEN-induced mutation in
exon 1 of each RHD allele in E1_B was observed at frequencies of
8/15 and 7/15, respectively, indicating that the mRNAs are
transcribed from both alleles and faithfully contain the mutation
from each allele in the genomic DNA.
Electrophoresis showed that the RT–PCR products from E4_M
(two weak bands at 1.4 and 1.3 kb and a very faint band at 1.1 kb)
were similar in size to those from unmodiﬁed cells; however, all
band intensities in the E4_M samples were proportionally weaker.
Sequencing showed that the transcript variant expression pattern
in E4_M was similar to that in unmodiﬁed cells and that the
mutated sequence of one RHD allele in E4_M was not observed in
mRNA. These results suggest that the majority, if not all, of the
observed RHD mRNA in E4_M is expressed from the unmodiﬁed
allele.
Absence of D antigen in the RHD-knockout clones. We next
evaluated D antigen protein expression on each HiDEP-1 cell
clone using ﬂow cytometry. As positive and negative controls for
this analysis, we used peripheral blood cells isolated from
Rh D-positive and -negative donors, respectively. Among
glycophorin Aþ cells, the D antigen expression rate was
99.96±0.004% and 1.4±0.6% in Rh D-positive and -negative
blood cells, respectively (Fig. 5), suggesting that ﬂow cytometry is
a sensitive way to detect D antigen expression with an B1%
nonspeciﬁc background signal.
Each clone was induced for differentiation towards erythro-
cytes for 4 days and subjected to ﬂow cytometry. Most of the
undifferentiated and differentiated HiDEP-1 cells were glyco-
phorin Aþ (Supplementary Fig. 8). Among the glycophorin Aþ
cells, the majority of cells in the parental and monoallelic mutant
clone populations showed signiﬁcant D antigen expression
(Fig. 5; Parental clone: 93±0.9%, monoallelic mutant clone:
73±2%). However, the percentage of cells expressing D antigen
in the monoallelic mutant clone was signiﬁcantly lower than that
in the parental clone (Po0.001, analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparison), indicating
the monoallelic mutation reduced D antigen expression. The
D antigen expression in the parental clone was slightly, but
signiﬁcantly, lower than that in the Rh D-positive blood cells
(Po0.01, ANOVA followed by Bonferroni’s multiple compar-
ison). The two RHD biallelic mutant clones expressed D antigen
at a level that was similar to the nonspeciﬁc background level
(E1_B, 1.8±0.2%; E4_B, 1.4±0.1%), suggesting the absence of
D antigen expression in these TALEN-induced RHD-biallelic
mutant clones.
Agglutination test of the RHD-knockout clones. We next
performed an agglutination test, which is used for blood group
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Figure 4 | RHD mRNA in the mutated clones. RT–PCR was performed to
detect RHD mRNA in each clone and the amplicons were subjected to
electrophoresis (a) and sequencing (b). (a) Representative pictures of
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typing. Parental, RHD-knockout (E1_B, E4_B) and RHD-mono-
allelic mutant (E4_M) HiDEP-1 cells were induced for differ-
entiation for 4 days and subjected to the agglutination test using
anti-D blood grouping reagents. The mixture of cells and anti-D
reagent was incubated for 15min at 37 C, shaken with pipet tips
and observed in 96-well plates and on glass slides. As positive
and negative controls, we used Rh D-positive and -negative
blood cells, which showed agglutination and no agglutination,
respectively (Fig. 6a, Supplementary Fig. 9). Parental and E4_M,
but not E1_B and E4_B, showed agglutination, suggesting that
E1_B and E4_B are phenotypically Rh D-negative.
Weak D-positive cells, like D-negative cells, can also show
‘no agglutination’ by the conventional agglutination testing
described above. To rule out the possibility of weak D, we next
performed a weak D detection test using E1_B and E4_B
including Rh D-negative and weak D-positive blood cells as
negative and positive controls, respectively. This test revealed no
agglutination in either clone (Fig. 6b), demonstrating that the two
RHD-knockout clones are D-negative rather than being weak
D-positive.
Differentiation and function of the RHD-knockout clones.
We evaluated whether TALEN-induced RHD knockout affects
erythrocyte generation from the erythroid progenitor cells or the
oxygen-carrying functions. Parental and E1_B cells were induced
for differentiation into erythrocytes as previously reported by
our group19. Morphological analysis showed that erythrocyte
differentiation was comparable among parental, E1_B, E4_B and
E4_M clones (Fig. 7a), suggesting that TALEN-induced RHD
knockout does not affect this process. Furthermore, the average
cell size during differentiation was similar among the parental
and three mutant clones (Fig. 7b), supporting that RHD knockout
does not inﬂuence differentiation. Moreover, ﬂow cytometry
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showed that, after the induction of differentiation, the expression
levels of erythroblast markers such as glycophorin A and CD71
were similar between the parental and three mutant clones
(Supplementary Fig.10), corroborating that RHD knockout does
not affect differentiation. For a functional comparison between
the parental line and three mutant clones, we measured their
oxygen-carrying abilities. The oxygen binding and dissociation
curves obtained were similar for each of these cell types (Fig. 7c),
indicating that the TALEN-induced RHD mutation does not
affect red blood cell function. Taken together, these results
indicate that erythrocyte differentiation and oxygen-carrying
functions are not affected by the TALEN-induced RHD mutation.
Discussion
Conversion of other blood groups into the O Rh D-negative
group has been studied in transfusion medicine for many years
because universal donor blood cells can be transfused into
patients when blood group-matched donor cells are not available
or in an emergency situation when blood group determination
cannot be readily achieved. The conversion of the A or B blood
group into O has been accomplished using enzymatic reactions
because ABO blood group determination depends on glycosyl-
transferase activity, the results of which can be reversed using
available exoglycosidases1–4. However, similar enzymatic
manipulations are not applicable to Rh D blood group
conversion because the Rh D blood group is determined by
antigenic RHD protein expression, not by the activity of certain
enzymes. Here we showed that TALEN-based disruption of RHD
can convert homozygous dominant Rh D-positive cells into
D-negative cells.
The main achievement of programmable nuclease-induced
gene knockout to date has been the determination of the
functions of genes24–26 and noncoding elements27–29 in cells or
organisms. In addition, such gene disruption has also been
utilized to treat human immunodeﬁciency virus infection30–32.
Here, for the ﬁrst time, we expanded the application of
programmable nuclease-mediated gene disruption to blood
group conversion.
Given that the different types of programmable nucleases share
genome-editing abilities and mechanisms13, we can assume that
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conversion into Rh D-negative cells could be achieved using other
programmable nucleases such as ZFNs and RGENs. Furthermore,
our study also raises the possibility that programmable nuclease-
mediated gene editing could lead to blood group conversion in
other blood group systems as well. For example, as the ABO
blood group is determined by ABO, programmable nuclease-
mediated knockout of ABO could lead to the generation of O
blood-type cells from A, B or AB blood-type cells. Programmable
nuclease-directed double knockout of ABO and RHD in erythroid
progenitor cells or haematopoietic stem cells would enable the
generation of O Rh D-negative blood type, universal donor blood
cells.
In the E1_B and E4_B clones, the absence of D antigen
expression was validated using ﬂow cytometry and agglutination
assays. For E1_B, given that a signiﬁcant amount of RHD mRNA
was expressed and that the mRNAs contain PTCs in exon 1, the
absence of D antigen would be attributable to PTC-induced
translational termination or nonsense-mediated translational
repression33,34. This lack of D antigen expression in the
presence of a signiﬁcant level of RHD mRNA in E1_B is in
contrast to the signiﬁcant D antigen expression and reduced
mRNA level in E4_M. The reduction of the RHD mRNA level in
E4_M would be attributable to a lack of mRNA expression from
the mutated allele, given that mRNA containing the mutation in
exon 4 was not detected using mRNA sequencing. As the
mechanism underlying this lack of mRNA from the mutated
allele, we cannot rule out nonsense-mediated decay, although the
mutation-induced PTC was 41 nucleotides upstream of the
exon 4 terminus, which does not satisfy the ‘50–55 nucleotide
rule’35–39. In E4_B, aberrant splicing and a decrease in mRNA
expression was observed. The aberrant splicing might be caused
by mutation themselves or by nonsense-mediated alternative
splicing, which was induced by PTCs that were generated by
mutations. Given that the PTCs generated by the two mutations
in E4_B cells satisfy the ‘50–55 nucleotide rule’, the decrease in
mRNA could be attributable to nonsense-mediated decay.
Although the D antigen was not detected using ﬂow cytometry
and agglutination assays in this study, we cannot rule out the
possibility that our approach could lead to partial RHD protein
expression. This partially expressed protein could still be
antigenic, which could cause clinical problems, but might be
hard to detect using antibody-mediated analyses such as
ﬂow cytometry and agglutination assays. In some cases,
nuclease-induced mutations could create new epitopes as
reported in previous studies in which mutations led to partial
D expression40,41. Regarding such partial protein expression,
genetic analysis or genomic DNA sequencing can reduce the
false-negative rate of serological analysis42. If PTCs are in the
transmembrane domain encoded by the RHD exon 1, expression
of the extracellular region would be absent and, thus, the resulting
protein would not cause clinical problems. In clone E1_B of this
study, the PTCs are in the extracellular domain encoded by exon
1 and the resulting expected extracellular domain is only two and
six-amino acids in length (Supplementary Fig. 6); such short
regions have a low, if not zero, possibility of serving as antigens.
For clone E4_B, we cannot rule out the possibility of potentially
problematic partial expression of the ﬁrst to third RHD
extracellular domains because the PTCs are in exons 4 and 5.
100
80
60
40
20
0
0 Day
Polychromatic erythroblasts
Basophilic erythroblasts
14
12
10
8
6
0 4 8 12
Parental 100
80
O
xy
ha
em
og
lo
bi
n 
(%
)
60
40
20
0
0 50 100
PB
Parental
150
pO2 (torr)
E1_B
E4_B
E4_M
Pa
ren
tal
E1
_B
E4
_B
E4
_M
Pa
ren
tal
E1
_B
E4
_B
E4
_M
Pa
ren
tal
E1
_B
E4
_B
E4
_M
Pa
ren
tal
E1
_B
E4
_B
E4
_M
E1_B
E4_B
E4_M
Days
Ce
ll s
ize
 (μ
m
)
Pe
rc
en
ta
ge
 (%
)
4 Days 8 Days
Reticulocytes
Orthochromatic erythroblasts
12 Days
Figure 7 | The RHD mutation does not affect the differentiation and function of HiDEP-1. (a,b) At the indicated times after the induction of erythrocyte
differentiation, differentiation of each HiDEP-1 cell line was quantiﬁed using microscopy after Wright–Giemsa staining. (a) Morphological analysis of
differentiation. The sum of two independent experiments is shown. (b) Cell size during differentiation. ANOVA showed that the cell sizes were the same in
the parental and RHD-mutant clones. Error bars represent the s.e.m. n¼ 3. (c) Oxygen equilibrium curves of parental and RHD-mutant clones (E1_B, E4_B
and E4_M). Human adult peripheral blood (PB) cells were used as the control.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8451 ARTICLE
NATURE COMMUNICATIONS | 6:7451 | DOI: 10.1038/ncomms8451 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
Thus, the possibility of problematic partial protein expression
may be reduced by the proper selection of clones, in this case by
choosing clone E1_B instead of E4_B.
Compared with the previously reported enzymatic digestion of
antigenic carbohydrate as a method for converting other blood
groups into group O1–4, our approach has advantages and
disadvantages. Our approach can be applied to progenitor or
stem cells that can give rise to numerous erythrocytes. In vivo or
ex vivo application of programmable nucleases to haematopoietic
stem cells would lead to the generation of an almost unlimited
number of erythrocytes with a converted blood group. However,
such gene editing cannot be applied to enucleated mature
erythrocytes, in contrast to enzymatic digestion. Given that the
mechanisms for blood group conversion are different between the
two approaches, they could potentially be combined to create a
very effective system for converting blood groups.
The absence or extremely suppressed expression of Rh antigens
can lead to Rhnull or Rhmod disease, which is characterized with a
mild to moderate haemolytic anaemia associated with stomato-
cytosis and plasma membrane abnormalities22,43. Because most
of the differentiated cells in this study were reticulocytes,
we could not determine whether RHD mutations cause
stomatocytosis, although we did not observe any stomatocytes
in the differentiated parental and mutant clones. Rhnull or Rhmod
disease can be caused by RHAG mutations alone or RHCE
mutations combined with an RHD deletion22. Using the two
TALEN pairs in this study, the possibility of generating the
RHAG mutation would be extremely low because potential off-
target sites were not found in RHAG. In the RHCE gene, potential
off-target sites were found for both TALEN pairs. However,
biallelic mutations in RHCE were found in only one clone out of
the three RHD-mutant clones. These biallelic mutations were
both in-frame, leading to minor changes (that is, one and two
amino acid deletions) in Rh C, e, E or e antigens. Taken together,
these observations suggest that the possibility of Rhnull or Rhmod
disease being caused by our approach would be low, although
we cannot rule it out. To prevent such a disease, we can select
RHD-mutant clones that do not have mutations in RHCE or use
programmable nucleases that do not have off-target effects on
RHCE.
Here we used Rh D-positive cells as a source for erythroid
progenitor cells. Instead, one could use cells derived from an Rh
D-negative donor as the source for erythroid progenitor cells,
which would not necessitate the programmable nuclease-
mediated blood group conversion. However, for some ethnic
groups, the availability of Rh D-negative donors matched for
other minor antigens could be much lower than that of Rh
D-positive donors matched for other minor antigens. Further-
more, the genetic diversity of the RH locus exceeds all estimates
predicted by serology44, and Rh serologic phenotype-matched
transfusion from minority donors does not prevent all cases of Rh
alloimmunization in patients with sickle cell disease45. Thus, our
approach of Rh antigen knockout would be a useful means of
preventing alloimmunization.
In summary, here we showed that TALENs can induce the
conversion of D-positive cells into D-negative cells by disrupting
RHD, expanding the application of programmable nucleases into
blood group conversion. This nuclease-based blood group gene
editing opens new avenues for the development of methods for
converting blood groups in transfusion medicine.
Methods
Cell culture. The Rh-positive blood group (homozygous dominant (DD))
erythroid progenitor cell lines HiDEP-1 and HUDEP-2 were derived from human-
induced pluripotent stem cells and human umblical cord blood cells, respectively19,
and are available from Dr Yukio Nakamura (email: yukionak@brc.riken.jp) on
request. We maintained these cells in a serum-free StemSpan SFEM medium
(StemCell Technologies, Vancouver, BC, Canada), without feeder cells in the
presence of doxycycline (1 mgml 1; Sigma, St Louis, MO, USA), erythropoietin
(EPO; 3 IUml 1; CJ Phama, Seoul, South Korea) and dexamethasone (10 6 M;
Sigma). Cord blood was collected from normal full-term deliveries in bags
containing 24.5ml of citrate phosphate dextrose A (Green Cross Corp., Yong-in,
Korea) under the approval of the Severance Hospital Institutional Review Board.
Red blood cells were removed using Ficoll-PaqueTM PLUS (density, 1.077;
GE Healthcare, Uppsala, Sweden) according to the manufacturer’s instructions.
CD34þ cells were isolated using a CD34 MicroBead Kit (Miltenyi Biotech,
Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Cord
blood CD34þ cells were induced to differentiate into the erythroid lineage for
17 days as follows23. From day 0 to 7, sorted CD34þ cells were continually
cultured in serum-free culture medium supplemented with 100 ngml 1 stem cell
factor (Peprotech, Rehovot, Israel), 10 ngml 1 interleukin-3 (Peprotech) and
6 IUml 1 recombinant EPO (Recormon Epoetin beta, Roche Diagnostic) with a
half-volume medium change twice a week. Serum-free culture medium consisted of
StemPro-34 SFM Complete Medium supplemented with 1% bovine serum albumin
(Sigma), 150 mgml 1 iron-saturated human transferrin (Sigma), 50 mgml 1
insulin (Sigma), 90 ngml 1 ferrous nitrate (Sigma), 2mM l-glutamine (Sigma),
1.6 10 4 M monothioglycerol (Sigma), 30.8 mM vitamin C (Sigma), 2 mgml 1
cholesterol (Sigma) and 1% penicillin–streptomycin solution (Gibco). In the
second 7-day period of culture, the medium was replaced with serum-free culture
medium with 3 IUml 1 recombinant EPO, 50 ngml 1 stem cell factor and
10 ngml 1 interleukin-3 to induce cell expansion and differentiation. During days
15 to 17 of culture, only one cytokine (EPO, at 2 IUml 1) was used for erythrocyte
differentiation, and poloxamer 188 (Pluronic F68 (F68), Sigma; MW 8,400) was
added at a concentration of 0.05%. HEK293T (human embryonic kidney cell line)
cells were cultured in DMEM (Gibco-BRL) supplemented with 10% fetal bovine
serum (FBS, Gibco-BRL). Rh D-positive and Rh D-negative peripheral blood cells
were supplied by Severance Hospital Blood Bank (Seoul, South Korea).
TALENs targeting RHD. TALENs targeting exons 1 and 4 of the RHD gene were
designed to include a 50 thymine as the starting point of the TALE-binding sites26
(http://www.talenlibrary.net/); the plasmids encoding these TALENs were obtained
from ToolGen (Seoul, South Korea). The maps and sequences of the plasmids are
shown in Supplementary Note 1. These plasmids are available from Addgene,
TALEN library resource (http://www.talenlibrary.net) and ToolGen (Order
number H172187, H172190). The repeat variable diresidues used were NI, NN,
NG and HD for binding to adenine, guanine, thymine and cytosine in the target
sequence, respectively. The magnetic reporters were prepared as previously
described15. To evaluate TALEN activity, 3.0 mg of TALEN plasmids (a plasmid
encoding one TALEN and a plasmid encoding the other TALEN, each 1.5 mg) were
transfected into 293T cells using FuGENE HD Transfection Reagent (Roche
Diagnostics, Basel, Switzerland). After 72 h of transfection, cells were harvested and
subjected to the T7E1 assay.
Generation of RHD-knockout clones. HiDEP-1 cells were transfected with a total
4.5 mg of TALEN plasmids and reporters (1.5 mg plasmid encoding one TALEN,
1.5 mg plasmid encoding the other TALEN and 1.5 mg magnetic reporter plasmid)
using a Human CD34 cell nucleofector kit (Lonza, Basel, Switzerland) from the
Amaxa system. After incubation for 3 days at 37 C, the transfected HiDEP-1 cells
were mixed with magnetic bead-conjugated antibody against H-2Kk (MACSelect
Kk microbeads; Miltenyi Biotech) and incubated for 20min at 4 C. H-2Kkþ cells
were separated on a column (MACS LS column; Miltenyi Biotech) according to the
manufacturer’s instructions and seeded into 96-well plates at 0.25 cell per well.
The cells were cultured for 2 weeks and each obtained clone was transferred into
24-well plates for further expansion. RHD-knockout clones were identiﬁed using
the T7E1 assay and sequencing.
T7E1 assay. Genomic DNA was isolated using a Genomic DNA puriﬁcation
Kit (Promega, Fitchburg, WI, USA) according to the manufacturer’s instructions.
Owing to the high homology between RHD and RHCE, we performed nested PCR
using primers that bind speciﬁcally to RHD but not RHCE (Supplementary
Table 1). The PCR amplicons were denatured by heating, annealed to form
heteroduplex DNA, treated with 5 units of mismatch-sensitive T7 endonuclease 1
(New England Biolabs, Hitchin, UK) for 20min at 37 C and analysed by 2%
agarose gel electrophoresis. Mutation frequencies were calculated as previously
described on the basis of the band intensities using the Image J software and
the following equation46: mutation frequency (%)¼ 100 [1 (1 fraction
cleaved)1/2], where the fraction cleaved is the total relative density of the cleavage
bands divided by the sum of the relative density of the cleavage bands and uncut
bands. Uncropped images of gels shown in Figs 1b,c and 2b and Supplementary
Figs 3 and 6a,c are shown in Supplementary Figs 11a,b,12,13 and 14a,b,
respectively.
Sequencing analysis. PCR amplicons were puriﬁed using a Fragment DNA
Puriﬁcation Kit (iNtRON biotechnology, Seongnam, South Korea) and cloned into
the pGEM-T vector. Cloned plasmids were sequenced using a T7 primer
(Supplementary Table 1).
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RT–PCR of RHD mRNA. Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions
and subjected to reverse transcription using Oligo-dT primer (Qiagen, Hilden,
Germany) and AccuPower RT PreMix (Bioneer, Daejeon, South Korea) according
to the manufacturer’s instructions. The synthesized cDNA was subjected to PCR
using a pair of primers (Supplementary Table 1). The PCR amplicons were
analysed with 1% agarose gel electrophoresis and sequenced as described above.
Uncropped images of gels shown in Fig. 4a are shown in Supplementary Fig. 15.
Induction of differentiation into erythrocytes. Differentiation into erythrocytes
was induced by culturing the HiDEP-1 cells at 1 106 cells ml 1 in erythroid
differentiation medium; IMDM (Gibco-BRL) containing 10% human AB serum
(Sigma), a-tocopherol (20 ngml 1; Sigma), linoleic acid (4 ngml 1; Sigma),
cholesterol (200 ngml 1; Sigma), sodium selenite (2 ngml 1; Sigma),
holo-transferrin (200 ngml 1; Sigma), human insulin (10 mgml 1; Sigma),
D-mannitol (14.57mgml 1; Sigma), mifepristone (an antagonist of
glucocorticoid receptor, 1 mM; Sigma), and EPO (5 IUml 1)19.
Flow cytometry. Harvested cells were incubated with anti-D blood grouping
reagent (human IgG/IgM monoclonal; Millipore, Billerica, MA, USA; dilution
1:10), antigen-presenting cell-conjugated anti-human-CD235a (BD Biocsciences,
Franklin Lakes, NJ, USA; dilution 1:100) and phycoerythrin-conjugated anti-
human IgG (Fc g-speciﬁc; eBioscience, San Diego, CA, USA; dilution 1:100) in
100ml of staining medium (PBS (Sigma) containing 2% FBS) for 20min at room
temperature. Stained cells were analysed using FACS Cantos II (BD Biosciences)
and FlowJo (version X.0.7).
Morphological analysis. Cells (1 105 cells per slide) were centrifuged on slides
using cytocentrifuge (Cytospin 4, Thermo Scientiﬁc, Waltham, MA, USA; 113 g
(1,000 r.p.m.), 5min), stained with Wright–Giemsa dye (Sigma) and observed
using a microscope (BX51; OLYMPUS, Tokyo, Japan) and a camera (DP71;
OLYMPUS).
Agglutination assay. The differentiated HiDEP-1 cells and control red blood cells
were plated into 96-well plates at 1 106 cells per well in 10ml of PBS. Then, we
added 10 ml of anti-D blood grouping reagent to each well and incubated the cells
for 15min at 37 C. Incubated cells were stirred using pipette tips and observed
using a stereo zoom microscope (SZ61; OLYMPUS) and a camera (G10;
Canon, Tokyo, Japan). For observation at higher magniﬁcation, the cell mixture
was transferred to glass slides and observed using an inverted microscope
(IX71; OLYMPUS) and a camera (DP70; OLYMPUS).
Clones that do not agglutinate in the presence of anti-D blood grouping
reagents were subjected to a weak D test. We added 10 ml of anti-D blood grouping
reagent to Eppendorf tubes containing 2 106 cells in 10 ml PBS and incubated the
mixture for 15min at 37 C. After washing three times with PBS, the cells were
mixed with 10 ml anti-human IgG, -C3d (Ortho-Clinical Diagnostics, High
Wycombe, UK), plated into 96-well plate, centrifuged for 30 s at 198g (1,000 r.p.m.)
and observed as described above.
Functional analysis of haemoglobin. After washing with PBS, 5 107 cells per
group were subjected to the analysis. Oxygen equilibrium curves were determined
using a Hemox-Analyzer (TSC scientiﬁc, New Hope, PA, USA) according to the
manufacturer’s instructions23. Human adult peripheral blood cells were used as the
control.
Statistical analysis. All data were expressed as means±s.e.’s. Statistical analysis
was conducted using IBM SPSS Statistics (version 21; IBM corporation, Armonk,
NY, USA). ANOVA followed by multiple comparison with Bonferroni’s method
was performed. A P valueo0.05 was considered statistically signiﬁcant.
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